Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109064 | 0.81 | TOP1 (0.68) | TERTTOP1PYGMPYGL | |
| SCHEMBL4345171 | 0.78 | CA12 (0.50) | TOP1CA12CA1CA2CA7 | |
| SCHEMBL1600762 | 0.74 | TOP1 (0.53) | TERTTOP1PYGMPYGL | |
| Protocatechuic Acid SCHEMBL5459242 | 0.70 | TTR (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9768032 | 0.70 | TTR (0.49) | TERTTOP1ESR1ESR2TTR | |
| SCHEMBL13286773 | 0.70 | SERPINE1 (0.70) | TERTTOP1CA12CA1CA2 | |
| SCHEMBL2525246 | 0.67 | SERPINE1 (0.61) | TERTTOP1CA12CA1CA2 | |
| SCHEMBL13286874 | 0.66 | CA12 (0.62) | TOP1CA12CA1CA2CA7 | |
| SCHEMBL30674458 | 0.66 | NSD2 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8204859 | 0.66 | NSD2 (0.71) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | TERT 1094/4885TOP1 3007/4885CA12 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.